Egypt's c.bank chief tells AMF summit financial challenges require stronger supervisory action    Egypt's Top 50 Women launches national STEM & AI Challenge Competition    Egypt's PM reviews major healthcare expansion plan with Nile Medical City    Saudi c. bank cuts repo, reverse repo rates by 25 basis points    UN rejects Israeli claim of 'new Gaza border' as humanitarian crisis worsens    Deli Group breaks ground on new factory in 10th of Ramadan City    Egypt's Cabinet approves development of Nasser Institute into world-class medical hub    Egypt reports sharp drop in waste burning incidents during autumn 2025    Servier Egypt launches Tibsovo as first targeted therapy for IDH1-mutated cancers    UNESCO adds Egyptian Koshari to intangible cultural heritage list    Egypt's exports rise 28.2% in September 2025 as trade deficit narrows    Egyptian Cabinet prepares new data law and stricter fines to combat misinformation    Egypt, EBRD discuss boosting finance in petroleum, mining sectors    UNESCO adds Egypt's national dish Koshary to intangible cultural heritage list    Blair dropped from US Gaza governance plan after Arab objections    Egypt's Abdelatty urges rapid formation of Gaza stability force in call with Rubio    Egypt calls for inclusive Nile Basin dialogue, warns against 'hostile rhetoric'    Egypt joins Japan-backed UHC Knowledge Hub to advance national health reforms    Egypt recovers two ancient artefacts from Belgium    Egypt, Saudi nuclear authorities sign MoU to boost cooperation on nuclear safety    Giza master plan targets major hotel expansion to match Grand Egyptian Museum launch    Australia returns 17 rare ancient Egyptian artefacts    China invites Egypt to join African duty-free export scheme    Egypt calls for stronger Africa-Europe partnership at Luanda summit    Egypt begins 2nd round of parliamentary elections with 34.6m eligible voters    Egypt warns of erratic Ethiopian dam operations after sharp swings in Blue Nile flows    Egypt scraps parliamentary election results in 19 districts over violations    Filmmakers, experts to discuss teen mental health at Cairo festival panel    Egypt golf team reclaims Arab standing with silver; Omar Hisham Talaat congratulates team    Egypt launches Red Sea Open to boost tourism, international profile    Omar Hisham Talaat: Media partnership with 'On Sports' key to promoting Egyptian golf tourism    Sisi expands national support fund to include diplomats who died on duty    Egypt's PM reviews efforts to remove Nile River encroachments    Egypt resolves dispute between top African sports bodies ahead of 2027 African Games    Germany among EU's priciest labour markets – official data    Paris Olympic gold '24 medals hit record value    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Russia says it's in sync with US, China, Pakistan on Taliban    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



EIPICO targets 2023 start of Biosimilar Project with EGP 400-600m revenues in 1st year
Local market size for oncology and hormone-based products is estimated at EGP1.5bn, which is currently 100% imported
Alyaa Stohy Published in Daily News Egypt on 24 - 02 - 2021

The Egyptian International Pharmaceutical Industries Company (EIPICO) is looking to start operations at its Biosimilar Project in 2023, a source has exclusively told Daily News Egypt.
The source also said that the company is targeting EGP 400-600m in the first year of operations, which is expected to increase to EGP 2bn by 2030.
The local market size for the oncology and hormone-based products is estimated at around EGP1.5bn, that is currently 100% imported. With EIPICO being one of the first local producers in this area, the company expects to cover at least 50% of the local demand before exporting through its Biosimilar Project. The total cost of the project is around EGP1.2bn, to be financed using 1:1 debt to equity.
According to management, EIPICO secured the local currency denominated debt financing portion from local banks, with management also noting that the equity portion should be financed from the company's internal resources.
However, some of the company's shareholders favour the capital increase over internal financing, which means that a capital increase is on the table.
EIPICO plans to invest around EGP 169m in 2021, directed towards the purchase of new machinery for EIPICO 1 and EIPICO 2. These service the production and packaging of ointments and pills along with facility renovations.
The company plans to invest around EGP 800m over the next three years excluding the biosimilar project, directed towards operating, re-modelling and renewing the facilities machinery.
The company has invested around EGP 300-340m between 2019 and 2020, directed towards up-grading and renovating existing facilities, resulting in an increase of EGP 73m in revenues per annum.
EIPICO currently has a total portfolio of 611 products, of which 407 are registered, 129 are in the pipeline, 43 are veterinary, 30 are feed additives and two are biocides.
The company had 14 new launches in 2020, up from eight launches in 2019, translating into sales of EGP 39.1m (ex-factory) in 2020, and EGP 15.7m (ex-factory) in 2019.
The company's management has increased the prices of 29 products in 2020, compared to 12 products in 2019. This implies an increase of EGP 56.6m in sales (ex-factory) in 2020, compared to an increase of EGP 12.2m in sales (ex-factory) during 2019.
Management plans to focus on new launches at high ASP along with submitting re-pricing requests of the existing products to the regulatory authorities. This should bode well for the sales growth during 2021 and going forward.

Clic here to read the story from its source.